Navigation Links
New drug design technique could dramatically speed discovery process
Date:4/13/2010

COLUMBUS, Ohio Scientists here are taking the trial and error out of drug design by using powerful computers to identify molecular structures that have the highest potential to serve as the basis for new medications.

Most drugs are designed to act on proteins that somehow malfunction in ways that lead to damage and disease in the body. The active ingredient in these medicines is typically a single molecule that can interact with a protein to stop its misbehavior.

Finding such a molecule, however, is not easy. It ideally will be shaped and configured in a way that allows it to bind with a protein on what are known as "hot spots" on the protein surface and the more hot spots it binds to, the more potential it has to be therapeutic.

To accomplish this, many drug molecules are composed of units called fragments that are linked through chemical bonds. An ideal drug molecule for a specific protein disease target should be a combination of fragments that fit into each hot spot in the best possible way.

Previous methods to identify these molecules have emphasized searching for fragments that can attach to one hot spot at a time. Finding structures that attach to all of the required hot spots is tedious, time-consuming and error-prone.

Ohio State University researchers, however, have used computer simulations to identify molecular fragments that attach simultaneously to multiple hot spots on proteins. The technique is a new way to tackle the fragment-based design strategy.

"We use the massive computing power available to us to find only the good fragments and link them together," said Chenglong Li, assistant professor of medicinal chemistry and pharmacognosy at Ohio State and senior author of a study detailing this work.

Li likens the molecular fragments to birds flying around in space, looking for food on the landscape: the protein surface. With this technique, he creates computer programs that allow the
'/>"/>

Contact: Chenglong Li
cli@pharmacy.ohio-state.edu
614-247-8786
Ohio State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IGERT fellows to design biodevices using flexible electronics
2. Researchers successfully simulate photosynthesis and design a better leaf
3. Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree
4. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
5. HIV isolate from Kenya provides clues for vaccine design
6. Book is the first high-resolution digital mouse brain atlas designed for Web applications
7. Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design
8. Specially-designed soils could help combat climate change
9. Popcorn-ball design doubles efficiency of dye-sensitized solar cells
10. Biodesigns Rittmann offers promising perspectives on societys energy challenge
11. Whales and dolphins influence new wind turbine design
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
(Date:5/28/2015)... , May 28, 2015 Industry ... of a new report titled "Markets for Self-Healing ... polymers, inorganic capsule and vascular systems, biomaterials, relevant ... grow to around $2.7 billion by 2020. ... n-tech,s extensive coverage of smart materials. Other recent n-tech ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... is used to soothe every kind of pain, from simple ... is one of the most used nowadays. However, research carried ... University of Granada showed that taking paracetamol slows ... studies. Author of this work is Olga Garca Mart ...
... VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... credentials,used in biometric identification, today announced the expansion ... Eastern government. A new centralized high-volume card ... optical memory and the eye-readable data of,this state-of-the-art ...
... deepens customer relationships, WALL, N.J., Aug. 15 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended June 30, 2007. Total revenue ... 30, 2007 decreased 19% to $2.5 million from ...
Cached Biology News:Paracetamol, one of most used analgesics, could slow down bone growth 2LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3BIO-key Reports Second Quarter 2007 Results 2BIO-key Reports Second Quarter 2007 Results 3BIO-key Reports Second Quarter 2007 Results 4BIO-key Reports Second Quarter 2007 Results 5
(Date:5/30/2015)... (PRWEB) May 30, 2015 The ... novel research for bile duct cancer, announced today ... Research Fellowship Program. , The Foundation ... scientists throughout the country to raise awareness about ... will support research that opens new pathways for ...
(Date:5/30/2015)... 2015 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... BAX ) today announced data from PERSIST-1 – ... the treatment of myelofibrosis – in a late-breaking oral ... American Society of Clinical Oncology (ASCO), May 29-June 2, ... is an investigational oral multikinase inhibitor with specificity for ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today,announced ... that showed its,delivery technology, TPM, delivered leading pain-relief ... irritation of any kind., These results support ... a sustained release oxycodone patch for the management ...
... 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... a,leading European pharmaceutical and medical devices company, ... Vasogen,s Celacade(TM) System,in Germany. Celacade, a first-in-class ... that specifically targets the destructive chronic,inflammation underlying ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced ... Board of Directors. Mr. Turner brings over 25 years ... serve on,the company,s audit committee., "We are delighted ... S.,Henney, Chairman of the Board of Directors of SGX. ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
... production by luciferase-cDNA transfected cell lines has ... the development of reporter gene assays in ... indicator for the transcription of other genes. ... due to advantages such as high sensitivity ...
... Thermostable dUTPase The ... of high-fidelity PCR (using proofreading DNA ... present in PCR reactions and dNTP ... in a proofreading DNA polymerase reaction ...
Biology Products: